This material is an English translation of the press release announced on July 25, 2016 in Japanese, and the Japanese release is given priority about the content and the interpretation.

---

July 25, 2016

**Notification of the results of Phase III clinical study on HP-3060 in Japan (a transdermal system for the treatment of allergic rhinitis)**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga prefecture, Japan; Chairman and CEO: Hirotaka Nakatomi, hereinafter referred to as Hisamitsu) hereby announces the results of the Phase III clinical study for a transdermal drug for the treatment of allergic rhinitis in Japan (Development code: HP-3060, Active pharmaceutical ingredient: emedastine fumarate, hereinafter referred to as "the product").

In the Phase III clinical study, the efficacy and safety of administration of the product once per day were compared with a placebo and with a positive drug (oral drug) in patients with allergic rhinitis. As a result, a statistically significant difference was confirmed for improvement in the primary efficacy endpoint compared with the placebo group. For safety, no serious adverse reactions were observed.

The product is a systemic transdermal tape formulation developed by utilizing Hisamitsu's TDDS (Transdermal Drug Delivery System) technology. Hisamitsu expects it to be a new option for the treatment of allergic rhinitis by realizing its long-lasting effect by means of maintaining a stable blood drug concentration.

Hisamitsu aims to apply for manufacturing and marketing approval during FY 2016.